Skip to main navigation
Axsome Corporate Homepage
  • About Axsome
    • All
    • Overview
    • Management Team
    • Board of Directors
    • Intellectual Property
    • State Disclosures
  • Portfolio
    • All
    • Overview
    • Products Overview  down arrow
      • All
      • Overview
      • Auvelity® (dextromethorphan-bupropion)
      • Sunosi® (solriamfetol)
      • Symbravo® (meloxicam and rizatriptan)
    • Pipeline Overview  down arrow
      • All
      • Overview
      • AXS-05
      • AXS-12
      • AXS-14
  • Conditions
    • All
    • Overview
    • Depression
    • Migraine
    • Alzheimer’s Disease Agitation
    • Excessive Daytime Sleepiness
    • Narcolepsy
    • Fibromyalgia
    • Smoking Cessation
  • Axsome Corporate Homepage
  • Science
    • All
    • Overview
    • Medical Information U.S.
    • Medical Information Canada
    • Publications
  • Investors
    • All
    • Overview
    • Corporate Governance
    • Stock Information
    • Financial Information
    • News & Events
    • Webcasts & Presentations
    • Analyst Coverage
    • Shareholder Services
  • Careers
    • All
    • Overview
    • Current Opportunities

Events

Events

Events

News Releases Events

Upcoming Events

Date Event Supporting Materials
November 16, 2026 at 11:20 AM GMT
Add to calendar:
Add to Outlook
Add to Google Calendar
UBS Global Biopharma Conference 2026
Click here for Webcast
November 09, 2026 at 11:30 AM EST
Add to calendar:
Add to Outlook
Add to Google Calendar
Guggenheim 3rd Annual Healthcare Innovation Conference
Click here for Webcast

Past Events

Date Event Supporting Materials
November 02, 2026 at 8:00 AM EST
Axsome Third Quarter 2026 Financial Results
Click here for Webcast
May 01, 2026 at 8:00 AM EDT
AUVELITY in Agitation Associated with Dementia due to Alzheimer’s Disease FDA Approval Call
Click here for Webcast
AUVELITY in Agitation Associated with Dementia due to Alzheimer’s Disease FDA Approval Call Presentation 4.7 MB
  • About Axsome
    • All
    • Overview
    • Management Team
    • Board of Directors
    • Intellectual Property
    • State Disclosures
  • Portfolio
    • All
    • Products Overview
    • Products Overview
    • Auvelity™ (dextromethorphan-bupropion)
    • Sunosi® (solriamfetol)
    • Symbravo® (meloxicam and rizatriptan)
    • Pipeline Overview
    • AXS‑05
    • AXS‑12
    • AXS‑14
  • Conditions
    • All
    • Overview
    • Depression
    • Migraine
    • Alzheimer's
      Disease Agitation
    • Excessive Daytime
      Sleepiness
    • Narcolepsy
    • Fibromyalgia
    • Smoking Cessation
  • Science
    • All
    • Overview
    • Medical Information U.S.
    • Medical Information International
    • Publications
  • Investors
    • All
    • Overview
    • Corporate Governance
    • Stock Information
    • Financial Information
    • News & Events
    • Webcasts &
      Presentations
    • Analyst Coverage
    • Shareholder Services
  • Careers
    • All
    • Careers
    • Current Opportunities
Axsome
  • Contact Us
  • Privacy Notice
  • Terms of Use
  • See Axsome Therapeutics on LinkedIn

AXSOME and its logos are trademarks or registered trademarks of Axsome Therapeutics,Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2026 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, New York, NY, 10007 info@axsome.com